We observed that the DCIS risk for a woman with a CHEK2 mutation and a family history of breast cancer was greater (OR = 2.3, p = 0.003) than that of a CHEK2 mutation carrier who has no family history of breast cancer (OR = 1.4, p = 0.06). This evidence concerns the gene CHEK2 and breast carcinoma.